Last 7 days
2.9%
Last 30 days
2.4%
Last 90 days
8.1%
Trailing 12 Months
-25.1%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MDT | 105.5B | 30.8B | -7.09% | -24.59% | 25.94 | 3.43 | -3.19% | -17.38% |
SYK | 104.1B | 18.4B | 2.26% | 8.00% | 44.16 | 5.64 | 7.84% | 18.25% |
ISRG | 84.2B | 6.2B | -4.47% | -13.27% | 63.66 | 13.53 | 8.97% | -22.43% |
BDX | 67.4B | 19.0B | -5.16% | -6.78% | 41.86 | 3.55 | -0.43% | -8.78% |
EW | 49.8B | 5.4B | 2.41% | -25.12% | 32.74 | 9.26 | 2.86% | 1.25% |
MID-CAP | ||||||||
SWAV | 7.2T | 489.7M | 9.34% | 31.15% | 82.2K | 16.8K | 106.51% | 2464.23% |
PEN | 10.2B | 847.1M | -3.64% | 34.52% | -5.1K | 12.05 | 13.32% | -137.89% |
GMED | 5.2B | 1.0B | -11.64% | -20.31% | 30.19 | 5.09 | 6.76% | 24.45% |
IRTC | 3.5B | 410.9M | 4.51% | -3.13% | -29.82 | 8.43 | 27.29% | -14.60% |
TNDM | 2.7B | 801.2M | 1.13% | -58.87% | -28.25 | 3.34 | 14.00% | -707.69% |
SMALL-CAP | ||||||||
SILK | 1.7B | 138.6M | -15.68% | 29.18% | -30.43 | 12.07 | 36.62% | -10.44% |
AVNS | 1.3B | 820.0M | -8.35% | -12.22% | 25.89 | 1.59 | 10.13% | 701.59% |
BLFS | 853.3M | 154.8M | -6.04% | 0.61% | -8.2 | 5.51 | 60.29% | -2309.58% |
CSII | 828.4M | 239.8M | 0.30% | 1.49% | -21.88 | 3.45 | -4.74% | -31.15% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 0.3% | 5,382 | 5,364 | 5,355 | 5,357 | 5,233 |
Gross Profit | 1.7% | 4,302 | 4,232 | 4,165 | 4,102 | 3,984 |
S&GA Expenses | -0.8% | 1,568 | 1,581 | 1,568 | 1,533 | 1,494 |
R&D Expenses | -0.1% | 945 | 946 | 950 | 925 | 903 |
EBITDA | 4.1% | 1,926 | 1,850 | 1,824 | 1,905 | - |
EBITDA Margin | 3.8% | 0.36* | 0.34* | 0.34* | 0.36* | - |
Earnings Before Taxes | 4.9% | 1,767 | 1,684 | 1,668 | 1,749 | 1,702 |
EBT Margin | 4.6% | 0.33* | 0.31* | 0.31* | 0.33* | - |
Interest Expenses | -32.2% | 19.00 | 28.00 | 21.00 | 19.00 | 18.00 |
Net Income | 4.3% | 1,522 | 1,459 | 1,455 | 1,539 | 1,503 |
Net Income Margin | 4.0% | 0.28* | 0.27* | 0.27* | 0.29* | - |
Free Cahsflow | -6.7% | 974 | 1,044 | 1,265 | 1,432 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -4.0% | 8,293 | 8,638 | 8,425 | 8,420 | 8,503 |
Current Assets | -11.9% | 3,096 | 3,514 | 3,263 | 3,241 | 3,181 |
Cash Equivalents | -38.4% | 769 | 1,248 | 1,198 | 1,031 | 863 |
Inventory | 15.5% | 876 | 758 | 740 | 731 | 727 |
Net PPE | 4.2% | 1,633 | 1,566 | 1,560 | 1,552 | 1,547 |
Goodwill | 0.5% | 1,164 | 1,159 | 1,164 | 1,166 | 1,168 |
Liabilities | 2.7% | 2,486 | 2,420 | 2,482 | 2,575 | 2,667 |
Current Liabilities | 11.4% | 1,022 | 918 | 969 | 950 | 1,032 |
LT Debt, Non Current | 0.0% | 596 | 596 | 596 | 596 | 596 |
Shareholder's Equity | -6.6% | 5,807 | 6,218 | 5,944 | 5,845 | 5,836 |
Retained Earnings | 5.5% | 7,590 | 7,192 | 6,848 | 6,442 | 6,068 |
Additional Paid-In Capital | 2.9% | 1,969 | 1,915 | 1,853 | 1,769 | 1,700 |
Accumulated Depreciation | 14.6% | 750 | 655 | - | - | - |
Shares Outstanding | -1.8% | 608 | 619 | 620 | 621 | 624 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -6.9% | 1,218 | 1,309 | 1,531 | 1,725 | 1,732 |
Share Based Compensation | 3.0% | 127 | 123 | 119 | 114 | 109 |
Cashflow From Investing | 131.2% | 252 | -808 | -984 | -1,443 | -1,722 |
Cashflow From Financing | -96.1% | -1,584 | -808 | -699 | -450 | -356 |
Buy Backs | 80.4% | 1,727 | 958 | 859 | 616 | 513 |
39.6%
31.9%
8.1%
Y-axis is the maximum loss one would have experienced if Edwards Lifesciences was unfortunately bought at previous high price.
33.1%
35.4%
38.1%
56.8%
FIve years rolling returns for Edwards Lifesciences.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -12.31 | -678,508 | 2,579,490 | 0.07% |
2023-03-13 | Claro Advisors LLC | reduced | -15.7 | -206,942 | 405,058 | 0.13% |
2023-03-10 | MATHER GROUP, LLC. | added | 122 | 240,355 | 477,355 | 0.01% |
2023-03-10 | MATHER GROUP, LLC. | sold off | -100 | -402,000 | - | -% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -61.4 | -33,648,700 | 18,003,300 | 0.02% |
2023-03-10 | BAILLIE GIFFORD & CO | added | 0.77 | -3,216,020 | 32,492,000 | 0.03% |
2023-03-08 | Capital Asset Advisory Services LLC | new | - | 303,887 | 303,887 | 0.02% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -80.43 | -22,180,000 | 4,760,000 | 0.02% |
2023-03-03 | TIAA, FSB | reduced | -88.56 | -7,335,270 | 844,734 | -% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 72,412,600 | 72,412,600 | 0.90% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 8.34% | 51,559,391 | SC 13G/A | |
Feb 07, 2023 | blackrock inc. | 8.6% | 53,060,508 | SC 13G/A | |
Feb 09, 2022 | vanguard group inc | 7.86% | 49,076,649 | SC 13G/A | |
Feb 03, 2022 | blackrock inc. | 9.1% | 57,040,983 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 7.76% | 48,347,685 | SC 13G/A | |
Jan 29, 2021 | blackrock inc. | 9.4% | 58,596,560 | SC 13G/A | |
Feb 12, 2020 | vanguard group inc | 7.79% | 16,261,702 | SC 13G/A | |
Feb 05, 2020 | blackrock inc. | 8.7% | 18,200,799 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 34.98 -57.29% | 45.99 -43.85% | 62.21 -24.05% | 80.13 -2.17% | 94.13 14.92% |
Current Inflation | 32.13 -60.77% | 41.56 -49.26% | 55.09 -32.74% | 69.98 -14.56% | 81.59 -0.39% |
Very High Inflation | 28.63 -65.05% | 36.22 -55.78% | 46.71 -42.97% | 58.26 -28.87% | 67.21 -17.95% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 15, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | PRE 14A | PRE 14A | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Feb 21, 2023 | 8-K | Current Report | |
Feb 21, 2023 | 4 | Insider Trading | |
Feb 17, 2023 | 4 | Insider Trading | |
Feb 17, 2023 | 4 | Insider Trading | |
Feb 16, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-15 | Chopra Daveen | acquired | 200,802 | 45.2767 | 4,435 | cvp, tmtt |
2023-03-15 | Chopra Daveen | sold | -343,563 | 77.4662 | -4,435 | cvp, tmtt |
2023-03-14 | MUSSALLEM MICHAEL A | acquired | 1,033,900 | 35.1967 | 29,375 | chairman & ceo |
2023-03-14 | MUSSALLEM MICHAEL A | gifted | - | - | 9,500 | chairman & ceo |
2023-03-14 | MUSSALLEM MICHAEL A | sold | -1,542,510 | 77.6107 | -19,875 | chairman & ceo |
2023-03-14 | MUSSALLEM MICHAEL A | gifted | - | - | -9,500 | chairman & ceo |
2023-03-08 | Lemercier Jean-Luc M | acquired | 233,706 | 35.1967 | 6,640 | cvp, emeacla and japac |
2023-03-08 | Lemercier Jean-Luc M | sold | -510,996 | 76.9573 | -6,640 | cvp, emeacla and japac |
2023-03-08 | BOBO DONALD E JR | sold | -517,558 | 76.9603 | -6,725 | cvp,strategy/corp development |
2023-03-08 | BOBO DONALD E JR | acquired | 236,698 | 35.1967 | 6,725 | cvp,strategy/corp development |
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Income Statement [Abstract] | ||||
Net sales | $ 1,319.0 | $ 1,310.2 | $ 4,034.1 | $ 3,902.8 |
Cost of sales | 253.8 | 311.7 | 822.5 | 939.4 |
Gross profit | 1,065.2 | 998.5 | 3,211.6 | 2,963.4 |
Selling, general, and administrative expenses | 377.3 | 364.4 | 1,156.6 | 1,069.7 |
Research and development expenses | 233.6 | 238.0 | 713.0 | 670.3 |
Intellectual property litigation (income) expenses, net | (2.4) | 4.7 | 10.8 | 13.5 |
Change in fair value of contingent consideration liabilities, net (Note 7) | (12.5) | 1.1 | (36.3) | (106.0) |
Special charge (Note 3) | 66.8 | 0.0 | 66.8 | 0.0 |
Operating income | 402.4 | 390.3 | 1,300.7 | 1,315.9 |
Interest (income) expense, net | (6.9) | 0.8 | (8.4) | 1.5 |
Other expense (income), net | 2.0 | (1.4) | 1.0 | (11.3) |
Income before provision for income taxes | 407.3 | 390.9 | 1,308.1 | 1,325.7 |
Provision for income taxes | 63.8 | 50.8 | 184.6 | 157.9 |
Net income | $ 343.5 | $ 340.1 | $ 1,123.5 | $ 1,167.8 |
Earnings per share: | ||||
Basic (in dollars per share) | $ 0.55 | $ 0.55 | $ 1.81 | $ 1.87 |
Diluted (in dollars per share) | $ 0.55 | $ 0.54 | $ 1.79 | $ 1.85 |
Weighted-average number of common shares outstanding: | ||||
Basic (in shares) | 619.8 | 623.6 | 621.0 | 623.0 |
Diluted (in shares) | 624.5 | 631.7 | 626.9 | 631.0 |
CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 1,247.8 | $ 862.8 |
Short-term investments (Note 4) | 490.9 | 604.0 |
Accounts receivable, net of allowances of $7.5 and $9.3, respectively | 618.1 | 582.2 |
Other receivables | 43.3 | 82.7 |
Inventories (Note 2) | 757.8 | 726.7 |
Prepaid expenses | 88.4 | 85.2 |
Other current assets | 267.6 | 237.1 |
Total current assets | 3,513.9 | 3,180.7 |
Long-term investments (Note 4) | 1,381.0 | 1,834.2 |
Property, plant, and equipment, net | 1,566.4 | 1,546.6 |
Operating lease right-of-use assets | 87.7 | 92.1 |
Goodwill | 1,158.7 | 1,167.9 |
Other intangible assets, net (Note 3) | 266.5 | 323.6 |
Deferred income taxes | 347.5 | 246.7 |
Other assets (Note 5) | 316.5 | 110.8 |
Total assets | 8,638.2 | 8,502.6 |
Current liabilities | ||
Accounts payable | 154.9 | 204.5 |
Accrued and other liabilities (Note 2) | 739.5 | 802.3 |
Operating lease liabilities | 23.5 | 25.5 |
Total current liabilities | 917.9 | 1,032.3 |
Long-term debt | 596.2 | 595.7 |
Contingent consideration liabilities (Note 7) | 25.7 | 62.0 |
Taxes payable | 142.9 | 190.0 |
Operating lease liabilities | 67.1 | 69.1 |
Uncertain tax positions | 295.6 | 259.0 |
Litigation settlement accrual (Note 2) | 153.9 | 191.3 |
Other liabilities | 221.1 | 267.3 |
Total liabilities | 2,420.4 | 2,666.7 |
Commitments and contingencies (Note 11) | ||
Stockholders' equity | ||
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding | 0.0 | 0.0 |
Common stock, $1.00 par value, 1,050.0 shares authorized, 645.7 and 642.0 shares issued, and 619.4 and 624.1 shares outstanding, respectively | 645.7 | 642.0 |
Additional paid-in capital | 1,914.5 | 1,700.4 |
Retained earnings | 7,191.6 | 6,068.1 |
Accumulated other comprehensive loss (Note 12) | (256.0) | (157.7) |
Treasury stock, at cost, 26.3 and 17.9 shares, respectively | (3,278.0) | (2,416.9) |
Total stockholders' equity | 6,217.8 | 5,835.9 |
Total liabilities and stockholders' equity | $ 8,638.2 | $ 8,502.6 |